6-氨基-茚满-1-醇 | 866472-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 6-氨基-茚满-1-醇
• 英文名称: 6-Amino-2,3-dihydro-1H-inden-1-ol
• CAS: 866472-42-6
• 化学式: C₉H₁₁NO
• mdl: MFCD11858351
• 分子量: 149.192
• InChiKey: JNHXSWSVDTZYQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  6-氨基-茚满-1-醇 在 cerium(III) chloride heptahydrate 、 叠氮磷酸二苯酯 、 溶剂黄146 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium iodide 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 16.12h， 生成 2-[(3-aminoindan-5-yl)amino]-8-bromo-6-(2,6-dichlorophenyl)pyrido[4,3-d]pyrimidin-5-one hydrochloride
  参考文献：
  名称：

  [EN] PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS
  [FR] DÉRIVÉS DE PYRIDOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE KINASE WEE1

  摘要：

  本公开提供了化合物或其药学上可接受的盐，并提供了使用这些化合物抑制Weel激酶和治疗例如患癌症的受试者的方法。所要求的化合物包括化合物（I）。

  公开号：

  WO2022256680A1
• 作为产物：
  描述：

  6-硝基-1-茚满酮 在 palladium on activated charcoal 氢气 作用下， 生成 6-氨基-茚满-1-醇
  参考文献：
  名称：

  M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: Serominic compounds

  摘要：

  Chronic low-dose treatment of rats with the psychomimetic drug, phencyclidine, induces regionally specific metabolic and neurochemical changes in the CNS that mirror those observed in the brains of schizophrenic patients. Recent evidence suggests that drugs targeting serotoninergic and muscarinic receptors, and in particular 5-HT7 antagonists and M-4 agonists, exert beneficial effects in this model of schizophrenia. Compounds that display this combined pattern of activity we refer to as serominic compounds. Based upon leads from natural product screening, we have designed and synthesised such serominic compounds, which are principally arylamidine derivatives of tetrahydroisoquinolines, and shown that they have the required serominic profile in ligand binding assays and show potential antipsychotic activity in functional assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.093

文献信息

• [EN] SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] PYRROLO[1,2-A]PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2016073891A1

  公开（公告）日：2016-05-12

  The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[l,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

  该发明提供了取代的吡咯并[1,2-a]嘧啶和相关的有机化合物，包含这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症等。本文描述的示例取代的吡咯并[1,2-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基吡咯并[1,2-a]嘧啶-8-羧酰胺化合物及其变体。
• Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2116547A1

  公开（公告）日：2009-11-11

  The invention relates to compounds (I) having pharmacological activity towards the 5-HT6 receptor, and more particularly to some N-imidazo[2,1-b]thiazole-5-sulfonamide derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT6 is involved.

  该发明涉及具有对5-HT6受体具有药理活性的化合物(I)，更具体地涉及一些N-咪唑[2,1-b]噻唑酮-5-磺酰胺衍生物，以及制备这些化合物的方法，包括含有它们的药物组合物，以及它们用于治疗和/或预防涉及5-HT6的疾病。
• Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2116546A1

  公开（公告）日：2009-11-11

  The invention relates to compounds having pharmacological activity towards the 5-HT6 receptor, and more particularly to some N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT6 is involved.

  该发明涉及具有对5-HT6受体具有药理活性的化合物，更特别地涉及一些N-苯基-2,3-二氢咪唑[2,1-b]噻唑-5-磺酰胺衍生物，以及制备这些化合物的方法，包括含有它们的药物组合物，以及它们用于治疗和/或预防5-HT6参与的疾病。
• Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
  申请人：Lysosomal Therapeutics Inc.

  公开号：US10751341B2

  公开（公告）日：2020-08-25

  The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

  本发明提供了取代的吡咯并[1,2-a]嘧啶及相关有机化合物、含有此类化合物的组合物、医用试剂盒以及使用此类化合物和组合物治疗患者的内科疾病（如戈谢病、帕金森病、路易体病、痴呆症或多系统萎缩）的方法。本文所述的示例性取代吡咯并[1,2-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基吡咯并[1,2-a]嘧啶-8-甲酰胺化合物及其变体。
• SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
  申请人：Lysosomal Therapeutics Inc.

  公开号：EP3215509A1

  公开（公告）日：2017-09-13